This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nuttall, M. E. Articles by Gowen, M. Search for Related Content PubMed PubMed Citation Articles by Nuttall, M. E. Articles by Gowen, M.

Idoxifene: A Novel Selective Estrogen Receptor Modulator Prevents Bone Loss and Lowers Cholesterol Levels in Ovariectomized Rats and Decreases Uterine Weight in Intact Rats

Departments of Bone and Cartilage Biology, and Safety Assessment (SR), SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406

Address all correspondence and requests for reprints to: Mark E. Nuttall, Department of Bone and Cartilage Biology, SmithKline Beecham Pharmaceuticals, 709 Swedeland Road, P.O. Box 1539, King of Prussia, Pennsylvania 19406. E-mail: Mark-E-Nuttall{at}sbphrd.com

Idoxifene, a novel selective estrogen receptor modulator, was tested for its effects on bone loss, serum cholesterol, and uterine wet weight and histology in the ovariectomized (Ovx) rat. Idoxifene (0.5 mg/kg·day) completely prevented loss of both lumbar and proximal tibial bone mineral density (BMD). In an intervention study, idoxifene (0.5 and 2.5 mg/kg·day) completely prevented further loss of both lumbar and proximal tibial BMD during a 2-month treatment period commencing 1 month after surgery, when significant loss of BMD had occurred in the Ovx control group. Idoxifene reduced total serum cholesterol, which was maximal at 0.5 mg/kg·day. Idoxifene alone displayed minimal uterotrophic activity in Ovx rats and inhibited the agonist activity of estrogen in intact rats. Histologically, myometrial and endometrial atrophy were observed in both idoxifene and vehicle-treated Ovx rats.

In this report, we also provide molecular-based evidence to support the observations in vivo of a novel selective estrogen receptor modulator (SERM) mechanism of action in bone and endometrial cells. Idoxifene is an agonist through the estrogen response element (ERE) and exhibits similar postreceptor effects to estrogen in bone-forming osteoblasts. Idoxifene also stimulates osteoclast apoptosis, and these pleiotropic effects ultimately could contribute to the maintenance of bone homeostasis. However, idoxifene differs from estrogen in a tissue-specific manner. In human endometrial cells, where estrogen is a potent agonist through the ERE, idoxifene has negligible agonist activity. Moreover, idoxifene was able to block estrogen induced gene expression in endometrial cells, which is in agreement with the observation in the intact rat study. In the uterus, idoxifene has a pharmacologically favorable profile, lacking agonist and therefore growth-promoting activity. Together with its cholesterol lowering effect and lack of uterotrophic activity, these data suggest that idoxifene may be effective in the prevention of osteoporosis and other postmenopausal diseases without producing unwanted estrogenic effects on the endometrium.

This article has been cited by other articles:

				C. Lemieux, Y. Gelinas, J. Lalonde, F. Labrie, D. Richard, and Y. Deshaies The Selective Estrogen Receptor Modulator Acolbifene Reduces Cholesterolemia Independently of Its Anorectic Action in Control and Cholesterol-Fed Rats J. Nutr., September 1, 2005; 135(9): 2225 - 2229. [Abstract] [Full Text] [PDF]

				M. J. Perry, S. Gujra, T. Whitworth, and J. H. Tobias Tamoxifen Stimulates Cancellous Bone Formation in Long Bones of Female Mice Endocrinology, March 1, 2005; 146(3): 1060 - 1065. [Abstract] [Full Text] [PDF]

				D. Vanderschueren, L. Vandenput, S. Boonen, M. K. Lindberg, R. Bouillon, and C. Ohlsson Androgens and Bone Endocr. Rev., June 1, 2004; 25(3): 389 - 425. [Abstract] [Full Text] [PDF]

				G. Arpino, M. Nair Krishnan, C. Doval Dinesh, V. J. Bardou, G. M. Clark, and R. M. Elledge Idoxifene versus tamoxifen: a randomized comparison in postmenopausal patients with metastatic breast cancer Ann. Onc., February 1, 2003; 14(2): 233 - 241. [Abstract] [Full Text] [PDF]

				X. L. Ma, F. Gao, J. Chen, T. A. Christopher, B. L. Lopez, E. H. Ohlstein, and T.-L. Yue Endothelial protective and antishock effects of a selective estrogen receptor modulator in rats Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H876 - H884. [Abstract] [Full Text] [PDF]

				X. L. Ma, F. Gao, C.-L. Yao, J. Chen, B. L. Lopez, T. A. Christopher, J. Disa, J.-L. Gu, E. H. Ohlstein, and T.-L. Yue Nitric Oxide Stimulatory and Endothelial Protective Effects of Idoxifene, a Selective Estrogen Receptor Modulator, in the Splanchnic Artery of the Ovariectomized Rat J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 786 - 792. [Abstract] [Full Text]

				M. E. Nuttall, G. B. Stroup, P. W. Fisher, D. P. Nadeau, M. Gowen, and L. J. Suva Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells Am J Physiol Cell Physiol, November 1, 2000; 279(5): C1550 - C1557. [Abstract] [Full Text] [PDF]

				C. K. Osborne and S. A. W. Fuqua Selective Estrogen Receptor Modulators: Structure, Function, and Clinical Use J. Clin. Oncol., September 17, 2000; 18(17): 3172 - 3186. [Abstract] [Full Text] [PDF]

				J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]

				A. M. Badger, S. M. Blake, R. A. Dodds, D. E. Griswold, B. A. Swift, D. J. Rieman, G. B. Stroup, S. J. Hoffman, and M. Gowen Idoxifene, a Novel Selective Estrogen Receptor Modulator, Is Effective in a Rat Model of Adjuvant-Induced Arthritis J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1380 - 1386. [Abstract] [Full Text]